Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We read with great interest the commentary by Rutgeerts et al1 on the value of predicting patient responses from trough serum levels of monoclonal antibodies (mAbs) against tumour necrosis factor-α (TNF). In fact, we have proposed therapeutic monitoring for rational use of anti-TNF mAb for quite some time.2
The authors point to the importance of low drug trough levels and ask how this can be explained in the absence of anti-drug antibodies (ADAs). They also pose the question whether ADAs are not always detected by routine assays. From experience with anti-TNF-treated patients with rheumatoid arthritis (RA) and Crohn's disease (CD), we can say that standard solid-phase assays (ELISAs) often fail to detect ADA because of high background values, matrix effects, for example epitope masking, and inability to detect ADA in the presence of the drug itself. Furthermore, …
Competing interests KB has received lecture fees from Wyeth, Roche and Bristol-Myers Squibb and is a shareholder in Biomonitor A/S. OØT has received lecture fees from Schering-Plough, UCB and Zealand Pharma.
Ethics approval This study was conducted with the approval of the appropriate Danish medical ethics committees.
Provenance and peer review Not commissioned; not externally peer reviewed.